It’s no surprise that data plays a pivotal role in the biopharmaceutical industry. Parsing through the large amount of valuable data acquired during a product lifecycle and turning it into actionable knowledge is a critical task for drug development pre- and post-regulatory approval. At Cytovance Biologics, process characterization not only characterizes activities in the process validation landscape, but also provides a platform leveraging enablers that turn data into product and process knowledge. This ensures desired product quality and process consistency start to finish.
In this webinar, the featured speaker describes their process characterization services based on Quality by Design (QbD) principles, emphasizing risk and knowledge management and transforming data into the currency of product and process knowledge.
The speaker will cover the applications of:
- PC enablers, including a powerful data management platform — OSIsoft PI
- An effective statistical tool DoE (design of experiments)
- A machine learning technique known as SVEM (self-validating ensemble modeling) and
- A JMP Pro multi-purpose platform functional data explorer (FDE)
Through the integrated applications of DoE with SVEM and OSIsoft PI with FDE, statistical modeling transforms DoE and functional data, respectively, into actionable knowledge. Although there are many types of data, the webinar will focus primarily on DoE and functional data analysis.
The speaker will demonstrate the benefits of employing a definitive screening design, a super-saturated design that features fewer experimental runs in the JMP DoE platform and SVEM, which builds high-performance predictive models through auto-validation techniques. These predictive models can be constructed to support the efficient development of analytical procedures and drug processes. Moreover, much of the process data is generated as a time function. Therefore, different tools and techniques are required to handle the complexity of functional data.
This webinar highlights how turning data into knowledge can enhance process understanding. In addition, it explores how predictive models can be constructed using DoE data and validated in parallel via SVEM algorithms. This approach reduces the number of experimental runs required for a validated model. By integrating advanced enablers in the workflow like sophisticated statistical modeling techniques and real-time data collection, many of the challenges encountered throughout a product lifecycle can be overcome.
Register for this webinar to learn more about statistical modeling and process characterization.
Eliza Yeung, PhD, Associate Director of Process Characterization, R&D Services, Cytovance Biologics
Dr. Eliza Yeung has over 20 years of experience in biopharmaceuticals, contract research laboratories and contract manufacturing organizations. She currently leads the Process Characterization Services (PCS) within R&D Services at Cytovance Biologics. In this role, she focuses on managing numerous PCS activities across upstream, downstream and analytical groups for late clinical phase clients, establishing high-quality services through the integration of Quality by Design (QbD) into PCS by emphasizing risk and knowledge management and implementing lifecycle concepts for products, processes and analytical procedures.
Eliza is the subject matter expert in QbD, and DoE (SAS JMP). She has extensive experience in technical project management, analytical method development/validation and glycoprotein analysis. Prior to Cytovance, she held positions at ARL, Genzyme and Novazyme Pharmaceuticals, where she gained valuable knowledge in ICH guidelines, CMC and Phase-appropriate GMP requirements. Eliza holds a PhD in organic chemistry from the University of Chicago.Message Presenter
Who Should Attend?
- Process Characterization Professionals
- Process Development Scientists
- Analytical Development Scientists
- Data Scientists from pharmaceutical and biotech companies
- Managers and Directors from pharmaceutical and biotech companies
What You Will Learn
Attendees will learn about:
- A process characterization platform that leverages enablers that turn data into product and process knowledge
- The integrated applications of sophisticated statistical modeling techniques and real-time data collection via a powerful data management platform for the analysis of design of experiments (DoE) and functional data
Cytovance® Biologics is a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO) that excels in the rapid and cost-effective development and manufacture of large molecule APIs from both mammalian cell culture and microbial fermentation, such as monoclonal antibodies, fragment antibodies, bispecifics, enzymes, fusion proteins, vaccines and other biological products including plasmid DNA and cell-based therapeutics. In addition to our clinical and commercial cGMP API manufacturing services, Cytovance offers well integrated development services supporting the entire product lifecycle, including cell line development, cell banking, microbial strain development, process and analytical development, and process characterization. A centralized, responsive program management team coordinates all critical CMC activities for each client program around raw materials management, QC testing, ICH stability studies, and regulatory support. Our 140,000 sq. ft. state-of-the-art facilities in Oklahoma City are designed to meet U.S., EU, and other global regulatory standards.